Landos Biopharma, Inc.

Progenetics LLC

Ppl Therapeutics (scotland) Limited

Nimmune Biopharma, Inc.

Biotherapeutics, Inc.

Julian D Cooper

Josep Bassaganya-Riera

Raquel Hontecillas

Richard Gandour

Adria Carbo Barrios

Tanya K O'Sickey

William Hugold Velander

Angelika Elisabeth Schnieke

Stephen P Butler

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Lanthionine synthetase C-like 2-based therapeutics

A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence for gene rescue, and a signal sequence is active in directing newly expressed Factor IX into the milk of the animal at levels in an unactivated form that is suitable for subsequent processing for therapeutic applications in treating Hemophilia B. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. The applications include milk derivatives for oral delivery and oral tolerization in the treatment of Hemophilia B.

Production of high levels of transgenic factor IX without gene rescue, and its therapeutic uses

A non-human transgenic mammalian animal, as described above, contains one or more exogenous double stranded DNA sequence(s) stably integrated into the genome of the animal, which comprises trans-acting regulatory units controlling expression of DNA sequences encoding proteins to be secreted into the milk of transgenic mammals. The DNA sequence of the trans-regulatory gene encodes transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed on a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins which require specialized propeptides for proper post-translational processing is also described.

Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto

The present invention utilizes genetic engineering techniques to prepare non-human transgenic mammals that express human .alpha.-lactalbumin in their milk at a concentration of 2 mg/ml or greater. The invention also includes methods of preparing human .alpha.-lactalbumin in, for example, mice and cows. Also taught are methods for preparing human .alpha.-lactalbumin in which from one to four of its natural phenylalanine residues have been substituted by another amino acid.

.alpha.-lactalbumin gene constructs

Growing community of inventors

Blacksburg, VA, United States of America

Julian D Cooper